RPG Life Sciences Peer Comparison
NSE: RPGLIFE | BSE: 532983
₹2,586.80
₹-5.90
(-0.23%)
As on 27-Aug-2026 13:34IST
Market cap
₹4,280 Cr
Revenue (TTM)
₹734 Cr
P/E Ratio
35.8
P/B Ratio
6.7
Div. Yield
0.9 %
Edit
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
Market cap (₹ Cr) |
4,280 | 35,414 | 30,103 | 16,994 | 16,032 |
Revenue (₹ Cr) |
734 | 9,683 | 2,372 | 2,590 | 1,108 |
Net Profit (₹ Cr) |
119.45 | 1,018.97 | 497.77 | 603.02 | 270.18 |
Net Margin (%) |
15.74 | 10.47 | 20.72 | 22.63 | 23.29 |
RoE (%) |
20.13 | 21.30 | 28.49 | 19.61 | 14.45 |
Price to Earnings |
35.83 | 35.02 | 60.47 | 28.18 | 58.22 |
Price-To-Book |
6.73 | 6.76 | 14.89 | 4.88 | 7.73 |
Income Statement (₹ Cr)
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Operating Revenue
|
707.52 | 7,896.00 | 2,022.99 | 2,551.83 | 1,054.89 |
|
Total Income
|
733.10 | 7,968.78 | 2,053.15 | 2,612.24 | 1,107.25 |
|
Total Expenditure
|
559.55 | 6,427.14 | 1,448.49 | 1,754.55 | 686.95 |
|
EBITDA
|
147.97 | 1,468.85 | 574.50 | 797.28 | 367.94 |
|
Depreciation
|
21.48 | 384.13 | 91.74 | 75.36 | 74.46 |
|
EBIT
|
126.49 | 1,084.73 | 482.76 | 721.93 | 293.48 |
|
Interest
|
1.77 | 175.78 | 23.95 | 5.37 | 0.82 |
|
Other Income
|
25.58 | 72.79 | 30.17 | 60.41 | 52.36 |
|
Exceptional Items
|
3.90 | -10.38 | 76.40 | -25.66 | -3.28 |
|
Profit before Tax
|
154.20 | 971.35 | 488.98 | 751.31 | 344.65 |
|
Provision for Tax
|
39.03 | 263.88 | 124.98 | 186.83 | 85.42 |
|
Profit after Tax
|
115.17 | 707.47 | 364.00 | 564.48 | 259.23 |
Liabilities (₹ Cr)
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
605.35 | 4,446.19 | 1,874.47 | 3,332.13 | 2,017.06 |
|
Minority Interest
|
-- | 195.37 | -- | -- | -1.92 |
|
Non-Current Liabilities
|
27.24 | 811.91 | 345.47 | 142.73 | 47.58 |
|
Current Liabilities
|
160.57 | 2,668.27 | 710.20 | 682.24 | 169.08 |
|
Total Liabilities
|
793.16 | 8,121.73 | 2,930.14 | 4,157.10 | 2,231.79 |
Assets (₹ Cr)
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
233.68 | 3,565.87 | 1,447.01 | 1,333.54 | 981.68 |
|
Current Assets
|
559.48 | 4,555.86 | 1,483.13 | 2,823.56 | 1,250.11 |
|
Total Assets
|
793.16 | 8,121.73 | 2,930.14 | 4,157.10 | 2,231.79 |
|
Total Debt*
|
20.00 | 730.70 | 196.61 | 0.00 | 0.00 |
|
Net Current Assets
|
398.91 | 1,887.59 | 772.93 | 2,141.33 | 1,081.03 |
|
Contingent Liabilities
|
17.79 | 393.94 | 13.18 | 4.82 | 3.76 |
Cashflow (₹ Cr)
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
56.50 | 851.71 | 346.68 | 565.41 | 266.88 |
|
Cash Flow from Investing Activities
|
85.84 | -94.00 | -423.73 | -570.15 | -142.72 |
|
Cash from Financing Activities
|
-20.58 | -813.96 | 20.98 | -64.34 | -112.88 |
|
Net Cash Inflow / Outflow
|
121.76 | -56.25 | -56.08 | -69.08 | 11.28 |
Ratios
Profitability Ratios
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
ROCE (%)
|
26.99 | 22.49 | 27.50 | 24.61 | 18.04 |
|
ROE (%)
|
20.28 | 19.19 | 21.43 | 18.41 | 13.54 |
|
ROA (%)
|
15.89 | 8.94 | 14.25 | 14.27 | 12.15 |
|
EBIT Margin (%)
|
24.53 | 19.52 | 29.89 | 33.61 | 39.84 |
|
Net Margin (%)
|
15.71 | 8.88 | 17.73 | 21.61 | 23.41 |
|
Cash Profit Margin (%)
|
18.06 | 13.61 | 22.53 | 24.81 | 31.63 |
Growth Ratios
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
8.28 | 18.59 | 36.98 | 6.91 | -12.10 |
|
EBIT Growth (%)
|
0.14 | 19.81 | 75.89 | 19.60 | -23.76 |
|
Net Profit Growth (%)
|
-37.15 | 34.10 | 39.94 | 16.24 | -30.25 |
|
EPS Growth (%)
|
-37.15 | 30.75 | 39.94 | 16.05 | -29.80 |
|
Book Value Growth (%)
|
14.10 | 50.94 | 22.95 | 18.43 | 11.27 |
Valuation Ratios
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Price / Earnings
|
26.57 | 29.84 | 42.34 | 21.18 | 40.73 |
|
Price / Book Value
|
5.05 | 4.58 | 8.23 | 3.60 | 5.27 |
|
Dividend Yield (%)
|
1.30 | 0.28 | 0.28 | 0.51 | 0.74 |
|
EV/EBITDA
|
16.64 | 13.55 | 25.23 | 13.94 | 25.25 |
|
Market Cap (₹ Cr)
|
3,059.67 | 20,327.45 | 15,412.11 | 11,956.86 | 10,627.92 |
Solvency Ratios
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.03 | 0.16 | 0.10 | 0.00 | 0.00 |
|
Short term debt to equity ratio
|
-- | 0.11 | -- | -- | 0.00 |
|
Current Ratio
|
3.48 | 1.71 | 2.09 | 4.14 | 7.39 |
|
Quick Ratio
|
2.71 | 0.98 | 1.37 | 3.12 | 5.46 |
|
Interest Coverage
|
88.12 | 6.53 | 21.42 | 140.86 | 419.57 |
Operating Efficiency Ratios
| RPG Life Sciences | Emcure Pharmaceuticals | Neuland Lab | Alivus Life Sciences | Concord Biotech | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
16.49 | 25.36 | 26.76 | 42.05 | 43.63 |
|
Asset Turnover
|
1.04 | 1.01 | 0.79 | 0.65 | 0.49 |
|
Receivable days
|
49.08 | 87.83 | 77.32 | 144.58 | 169.86 |
|
Inventory Days
|
52.31 | 78.64 | 80.83 | 96.67 | 97.92 |
|
Payable days
|
138.22 | 174.97 | 125.94 | 135.45 | 159.68 |
|
Cash Conversion Cycle
|
-36.84 | -8.50 | 32.22 | 105.80 | 108.11 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
loading...
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
